Long-term Survival After Pancreatic Resection for Renal Cell Carcinoma Metastasis

被引:0
作者
L. Schwarz
A. Sauvanet
N. Regenet
J. Y. Mabrut
J. F. Gigot
E. Housseau
B. Millat
M. Ouaissi
B. Gayet
D. Fuks
J. J. Tuech
机构
[1] Hôpital Charles Nicolle,Department of Digestive Surgery
[2] Hôpital Beaujon,Department of Hepato
[3] Hôpital Hotel Dieu,biliary and Pancreatic Surgery
[4] Hôpital de la Croix Rousse,Department of Digestive Surgery
[5] Saint-Luc University Hospital,Department of Hepato
[6] Université Catholique de Louvain,biliary Surgery
[7] Hôpital Hautepierre,Department of Hepato
[8] Hôpital Saint Eloi,biliary and Pancreatic Surgery
[9] La Timone,Department of Hepato
[10] Institut Mutualiste Montsouris,biliary and Pancreatic Surgery
来源
Annals of Surgical Oncology | 2014年 / 21卷
关键词
Renal Cell Carcinoma; Lymph Node Involvement; Pancreatic Resection; Metastatic Renal Cell Carcinoma; Nonoperative Management;
D O I
暂无
中图分类号
学科分类号
摘要
引用
收藏
页码:4007 / 4013
页数:6
相关论文
共 154 条
[1]  
Cindolo L(2005)Comparison of predictive accuracy of four prognostic models for nonmetastatic renal cell carcinoma after nephrectomy: a multicenter European study Cancer. 104 1362-1371
[2]  
Patard JJ(2001)A postoperative prognostic nomogram for renal cell carcinoma J Urol. 166 63-67
[3]  
Chiodini P(2003)Prediction of progression after radical nephrectomy for patients with clear cell renal cell carcinoma: a stratification tool for prospective clinical trials Cancer. 97 1663-1671
[4]  
Kattan MW(2013)Time to recurrence is a significant predictor of cancer-specific survival after recurrence in patients with recurrent renal cell carcinoma–results from a comprehensive multi-centre database (CORONA/SATURN-Project) BJU Int. 112 909-916
[5]  
Reuter V(2005)Randomized phase III trial of high-dose interleukin-2 versus subcutaneous interleukin-2 and interferon in patients with metastatic renal cell carcinoma J Clin Oncol. 23 133-141
[6]  
Motzer RJ(1998)Recombinant human interleukin-2, recombinant human interferon alfa-2a, or both in metastatic renal-cell carcinoma. Groupe Francais d’Immunotherapie N Engl J Med. 338 1272-1278
[7]  
Katz J(2010)Phase III trial of bevacizumab plus interferon alfa-2a in patients with metastatic renal cell carcinoma (AVOREN): final analysis of overall survival J Clin Oncol. 28 2144-2150
[8]  
Russo P(2008)Bevacizumab plus interferon alfa compared with interferon alfa monotherapy in patients with metastatic renal cell carcinoma: CALGB 90206 J Clin Oncol. 26 5422-5428
[9]  
Leibovich BC(1998)Resection of metastatic renal cell carcinoma J Clin Oncol. 16 2261-2266
[10]  
Blute ML(1994)Surgeon’s role in the management of solitary renal cell carcinoma metastases occurring subsequent to initial curative nephrectomy: an institutional review Ann Surg Oncol. 1 345-352